CSTL CASTLE BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, CASTLE BIOSCIENCES INC reported revenue of $104M (up 20.1% from a year earlier), net income of −$2.06M and diluted EPS of −$0.07; over the last four quarters revenue was $357M and net income −$19.4M; for the fiscal year ended December 2025 revenue was $344M, up 3.7% on the year before.
CSTL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $344M, gross profit n/a, operating income −$42.8M, net income −$24.2M (margin -7.0%), EPS −$0.83
- Fiscal year ended Dec 2024: revenue $332M, gross profit n/a, operating income $8.67M, net income $18.2M (margin 5.5%), EPS $0.62
- Fiscal year ended Dec 2023: revenue $220M, gross profit n/a, operating income −$68.0M, net income −$57.5M (margin -26.1%), EPS −$2.14
- Fiscal year ended Dec 2022: revenue $137M, gross profit n/a, operating income −$72.9M, net income −$67.1M (margin -49.0%), EPS −$2.58
- Fiscal year ended Dec 2021: revenue $94.1M, gross profit n/a, operating income −$40.1M, net income −$31.3M (margin -33.3%), EPS −$1.24
CSTL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $104M (up 20.1% year over year), net income −$2.06M, EPS −$0.07
- Quarter ended Mar 31, 2026: revenue $83.7M (down 4.9% year over year), net income −$14.5M, EPS −$0.49
- Quarter ended Dec 31, 2025 (from the annual report): revenue $87.0M (up 0.8% year over year), net income −$2.33M, EPS −$0.06
- Quarter ended Sep 30, 2025: revenue $83.0M (down 3.2% year over year), net income −$501K, EPS −$0.02
- Quarter ended Jun 30, 2025: revenue $86.2M (down 0.9% year over year), net income $4.52M, EPS $0.15
- Quarter ended Mar 31, 2025: revenue $88.0M (up 20.6% year over year), net income −$25.8M, EPS −$0.90
- Quarter ended Dec 31, 2024 (from the annual report): revenue $86.3M (up 30.5% year over year), net income $9.59M, EPS $0.32
- Quarter ended Sep 30, 2024: revenue $85.8M (up 39.5% year over year), net income $2.27M, EPS $0.08
- Quarter ended Jun 30, 2024: revenue $87.0M (up 73.5% year over year), net income $8.92M, EPS $0.31
- Quarter ended Mar 31, 2024: revenue $73.0M (up 73.6% year over year), net income −$2.53M, EPS −$0.09
- Quarter ended Dec 31, 2023 (from the annual report): revenue $66.1M (up 72.5% year over year), net income −$2.58M, EPS −$0.08
- Quarter ended Sep 30, 2023: revenue $61.5M (up 66.1% year over year), net income −$6.91M, EPS −$0.26
- Quarter ended Jun 30, 2023: revenue $50.1M (up 43.9% year over year), net income −$18.8M, EPS −$0.70
- Quarter ended Mar 31, 2023: revenue $42.0M (up 56.6% year over year), net income −$29.2M, EPS −$1.10
- Quarter ended Dec 31, 2022 (from the annual report): revenue $38.3M (up 53.1% year over year), net income −$20.6M, EPS −$0.78
- Quarter ended Sep 30, 2022: revenue $37.0M (up 57.7% year over year), net income −$20.2M, EPS −$0.77
- Quarter ended Jun 30, 2022: revenue $34.8M (up 53.1% year over year), net income −$1.65M, EPS −$0.06
- Quarter ended Mar 31, 2022: revenue $26.9M (up 17.7% year over year), net income −$24.6M, EPS −$0.97
- Quarter ended Dec 31, 2021 (from the annual report): revenue $25.0M, net income −$6.43M, EPS −$0.25
- Quarter ended Sep 30, 2021: revenue $23.5M, net income −$11.8M, EPS −$0.47
CSTL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $64.3M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow $64.9M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$5.63M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$41.7M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow −$19.0M, share buybacks n/a, dividends $0.00 per share
CSTL balance sheet
- Jun 30, 2026: cash $62.1M, total assets $561M, total liabilities $91.1M, shareholders' equity $470M, long-term debt $7.16M
- Mar 31, 2026: cash $63.8M, total assets $548M, total liabilities $86.4M, shareholders' equity $461M, long-term debt $8.40M
- Dec 31, 2025: cash $117M, total assets $579M, total liabilities $108M, shareholders' equity $471M, long-term debt $9.64M
- Sep 30, 2025: cash $85.6M, total assets $563M, total liabilities $95.7M, shareholders' equity $467M, long-term debt $10.0M
- Jun 30, 2025: cash $82.2M, total assets $545M, total liabilities $89.4M, shareholders' equity $455M, long-term debt $8.10M
- Mar 31, 2025: cash $89.7M, total assets $502M, total liabilities $61.4M, shareholders' equity $440M, long-term debt $8.92M
- Dec 31, 2024: cash $120M, total assets $531M, total liabilities $75.4M, shareholders' equity $456M, long-term debt $9.75M
- Sep 30, 2024: cash $95.0M, total assets $515M, total liabilities $73.5M, shareholders' equity $441M, long-term debt $10.0M
What is CSTL's revenue?
CASTLE BIOSCIENCES INC reported $357M of revenue over its last four quarters, through June 30, 2026.
Is CSTL profitable?
No. CASTLE BIOSCIENCES INC lost $19.4M over the last four quarters.
What is CSTL's EPS?
Diluted earnings per share over the last four quarters were −$0.64; −$0.07 in the latest quarter.